Kaiseraugst (Switzerland), Heerlen (Netherlands), July 3, 2023
dsm-firmenich, innovators in nutrition, health, and beauty, confirms the completion of its acquisition of Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.
Postbiotics is a rapidly emerging segment of the health through the gut market, offering longer shelf-life and greater application versatility than probiotics while providing substantiated health benefits. With the benefits of their use supported by a growing body of robust scientific evidence, they represent the next wave of opportunity in the gut health market.
Philip Eykerman, dsm-firmenich’s President Health, Nutrition & Care, said: “Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for dsm-firmenich that will complement three of our four Business Units. The Adare Biome teams bring great knowledge in this area which will greatly help in driving our ‘Health from the Gut’ strategy and enable us to accelerate the creation of next-generation biotics to support the health of people and animals. We are excited about the new opportunities this move will unlock, as dsm-firmenich’s strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world. We welcome the Adare Biome team members to the dsm-firmenich family.”
dsm-firmenich intends to extend the availability of Adare Biome’s over the counter postbiotic supplement for relieving gut upsets Lactéol® through its B2C unit, i-Health. Further development of postbiotic B2B ingredients will include opportunities in dietary supplements, early life nutrition, medical nutrition, and nutritional improvement for the under-nourished. The acquisition of Adare Biome will also position dsm-firmenich as a leader in the growing microbiome management market for pets and expand its animal health range, where the stability of postbiotics means they can be incorporated into premix feed solutions.
Tom Sellig, CEO of Adare Pharma Solutions, commented: “dsm-firmenich is the ideal company to take Adare Biome to the next level and realize the growth potential of postbiotics. They have the infrastructure, together with strong commercialization and science capabilities, to scale the significant scientific research that we’ve achieved over the years. Moreover, dsm-firmenich’s purpose of bringing progress to life resonates strongly with the team.”
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people.
About Adare Biome
Adare Biome develops, produces, and commercializes high-quality postbiotic solutions, including its pharmaceutical product, Lactéol®, which is marketed in almost 40 countries around the world. Its ingredients, including LBiome™ and LBiotix™, are used for digestive health applications in human, pet, and production animals. Adare Biome is based in Houdan, France. More information can be found at www.adarebiome.com.
About Adare Pharma Solutions
Adare Pharma Solutions is a global, technology-driven CDMO providing product development through commercial manufacturing expertise, with a focus on oral dosage forms for the pharmaceutical industry. Adare’s specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactured more than 65 products sold by customers in more than 100 countries globally. More information can be found at www.adarepharmasolutions.com.